Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa

Journal of the Chinese Medical Association

Volumn 77, Issue 4, 2014, Pages 190-197

  Lin, Hsiang Yu ^a,b,c,d,e   Huang, Yu Hsiu ^a,e,f   Liao, Hsuan Chieh ^a,e,g   Liu, Hao Chuan ^e,f   Hsu, Ting Rong ^a,e,f   Shen, Chia I ^e,f   Li, Shao Tzu ^e,f   Li, Cheng Fang ^e,f   Lee, Li Hong ^e,f   Lee, Pi Chang ^f   Huang, Chun Kai ^e,f   Chiang, Chuan Chi ^e,g   Lin, Shuan Pei ^b,c,d   Niu, Dau Ming ^a,e,f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^e Taiwan Clinical Trial Consortium in Fabry Disease ^*  (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g Chinese Foundation of Health   (Taiwan)

Author keywords

Agalsidase alfa; Agalsidase beta; Enzyme replacement therapy; Fabrazyme; Fabry disease; Replagal

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; GLOBOTRIAOSYLSPHINGOSINE; SPHINGOSINE; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; END STAGE RENAL DISEASE; ENZYME REPLACEMENT; FABRY DISEASE; FEVER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINZ SEVERITY SCORE INDEX; MALE; MICROALBUMINURIA; MIDDLE AGED; PRURITUS; SCORING SYSTEM; TAIWAN; TREATMENT DURATION; URTICARIA; YOUNG ADULT;

EID: 84897573878     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.11.006     Document Type: Article

References (41)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease 2001, 3733-3774. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Zarate Y.A., Hopkin R.J. Fabry's disease. Lancet 2008, 372:1427-1435.
3. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
4. Monserrat L., Gimeno-Blanes J.R., Marín F., Hermida-Prieto M., García-Honrubia A., Pérez I., et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007, 50:2399-2403.
5. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333:288-293.
6. Sachdev B., Takenaka T., Teraguchi H., Tei C., Lee P., McKenna W.J., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002, 105:1407-1411.
7. Kotanko P., Kramar R., Devrnja D., Paschke E., Voigtlander T., Auinger M., et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004, 15:1323-1329.
8. Nakao S., Kodama C., Takenaka T., Tanaka A., Yasumoto Y., Yoshida A., et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003, 64:801-807.
9. Tanaka M., Ohashi T., Kobayashi M., Eto Y., Miyamura N., Nishida K., et al. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 2005, 64:281-287.
10. Rolfs A., Böttcher T., Zschiesche M., Morris P., Winchester B., Bauer P., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005, 366:1794-1796.
11. Lidove O., Joly D., Barbey F., Bekri S., Alexandra J.F., Peigne V., et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007, 61:293-302.
12. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
13. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007, 18:1547-1557.
14. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006, 21:345-354.
15. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007, 146:77-86.
16. Beck M., Ricci R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004, 34:838-844.
17. Thofehrn S., Netto C., Cecchin C., Burin M., Matte U., Brustolin S., et al. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience. Ren Fail 2009, 31:773-778.
18. Schwarting A., Dehout F., Feriozzi S., Beck M., Mehta A., Sunder-Plassmann G., et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006, 66:77-84.
19. Hoffmann B., Beck M., Sunder-Plassmann G., Borsini W., Ricci R., Mehta A., et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007, 23:535-542.
20. West M., Nicholls K., Mehta A., Clarke J.T., Steiner R., Beck M., et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009, 20:1132-1139.
21. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003, 108:1299-1301.
22. Imbriaco M., Pisani A., Spinelli L., Cuocolo A., Messalli G., Capuano E., et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009, 95:1103-1107.
23. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coghlan G., Brookes J., et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008, 94:153-158.
24. Lin H.Y., Liu H.C., Huang Y.H., Liao H.C., Hsu T.R., Shen C.I., et al. Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). BMJ Open 2013, 3. e003146.
25. Linthorst G.E., Germain D.P., Hollak C.E., Hughes D., Rolfs A., Wanner C., et al. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011, 102:99-102.
26. Smid B.E., Rombach S.M., Aerts J.M., Kuiper S., Mirzaian M., Overkleeft H.S., et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 2011, 6:69.
27. Tsuboi K., Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 2012, 14:779-786.
28. Lin H.Y., Chong K.W., Hsu J.H., Yu H.C., Shih C.C., Huang C.H., et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009, 2:450-456.
29. Lin H.Y., Huang C.H., Yu H.C., Chong K.W., Hsu J.H., Lee P.C., et al. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4+919G→A). J Inherit Metab Dis 2010, 33:619-624.
30. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
31. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
32. de Simone G., Daniels S.R., Devereux R.B., Meyer R.A., Roman M.J., de Divitiis O., et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992, 20:1251-1260.
33. de Simone G., Devereux R.B., Daniels S.R., Koren M.J., Meyer R.A., Laragh J.H. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995, 25:1056-1062.
34. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
35. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008, 105:2812-2817.
36. Rombach S.M., Dekker N., Bouwman M.G., Linthorst G.E., Zwinderman A.H., Wijburg F.A., et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 2010, 1802:741-748.
37. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004, 65:299-307.
38. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-266. National Kidney Foundation.
39. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
40. Vedder A.C., Linthorst G.E., Houge G., Groener J.E., Ormel E.E., Bouma B.J., et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007, 2:e598.
41. Mehta A., Beck M., Kampmann C., Frustaci A., Germain D.P., Pastores G.M., et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 2008, 95:114-115.